Although the study examined preferences on novel EGFR‐mutated NSCLC treatments including those effective to EGFR ex20in, the sample included patients with broader EGFR‐mutated NSCLC as it was too difficult to attain an exclusive sample of patients with NSCLC EGFR ex20in. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.